Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Stopped early · Phase 3

Conditions studied: Leukemia, Lymphoma

In brief

Objectives: * Determine the corrected count increment of autologous transfused platelets that had been stored by cryopreservation with ThromboSol. * Determine the ability of autologous platelets that had been stored by cryopreservation with ThromboSol to correct thrombocytopenia.

Key facts

Study ID

NCT00074763

Run by

M.D. Anderson Cancer Center

People needed

4

Starts

2003-07-01

Expected to finish

2006-01-01

Last updated by the study team

2012-08-02

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 1.- Patients in remission with ALL, CLL, AML, CML, MDS will be allowed to participate in this program if their platelet count is >150K, and the hemoglobin level is at least 8.0g/dl. The patient will receive their autologous platelets cryopreserved in ThromboSol or the fresh random platelets (FRP) whenever the need for such transfusions is determined to be clinically indicated by their physician(s).

You may not qualify if…

• Patients with detectable circulating malignant cells or ongoing marrow involvement by the tumor will not be eligible.

Where it is running

• UT M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.